NCT05133505

Brief Summary

Primary central nervous system diffuse large B cell lymphoma is a rare and aggressive entity of diffuse large B cell lymphoma. A previous transcriptomic study showed an overexpression of TIM-3 and Gal-9 in the tumor microenvironment. The investigators aimed to characterise TIM-3/Gal-9 immune checkpoints by using immunohistochemistry in the tumor microenvironment of primary central nervous system diffuse large B cell lymphoma.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
65

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2002

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2002

Completed
19.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2021

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

November 12, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

November 24, 2021

Completed
Last Updated

November 24, 2021

Status Verified

November 1, 2021

Enrollment Period

19.8 years

First QC Date

November 12, 2021

Last Update Submit

November 12, 2021

Conditions

Lymphoma, B-Cell

Outcome Measures

Primary Outcomes (1)

  • TIM-3 and Gal-9 immunohistochemical expression

    TIM-3 and Gal-9 immunohistochemical expression by tumor and microenvironment cells

    1 day

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patient of Primary central nervous system diffuse large B cell lymphoma

You may qualify if:

  • \- patient with a Diagnosis of LBDGC-SNC

You may not qualify if:

  • immunocompromised patients
  • patients with a history of previous or associated low-grade lymphoma
  • patients with a history of systemic LBDGC with secondary localization to the SNC

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Uh Montpellier

Montpellier, 34295, France

Location

MeSH Terms

Conditions

Lymphoma, B-Cell

Condition Hierarchy (Ancestors)

Lymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • aline desrumaux, MD, PhD

    University Hospital, Montpellier

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 12, 2021

First Posted

November 24, 2021

Study Start

January 1, 2002

Primary Completion

October 1, 2021

Study Completion

November 1, 2021

Last Updated

November 24, 2021

Record last verified: 2021-11

Locations

FR(1)